The 2026 ASGCT Annual Meeting will grandly kick off from May 11th to 15th at the Boston Convention and Exhibition Center! As the world’s top large-scale international academic exchange and industrial cooperation event focusing on cell and gene therapy, the ASGCT Annual Meeting has been successfully held annually since its founding. It serves as a core window showcasing global cutting-edge innovations in gene editing, cell therapy and biopharmaceutical research, an important platform for deepening international academic exchanges and industry collaboration in the life science sector, and a key driver for boosting the innovative development of global biomedical technology.

 

MingCeler Biotech, a professional R&D service provider dedicated to animal model technology and customized genetically modified mouse model development, is honored to participate in this prestigious annual event. We specialize in delivering fast, stable and personalized custom animal model solutions for global pharmaceutical enterprises, research institutions and academic laboratories. We will showcase our core technologies, innovative products and one-stop research services at the conference, joining industry peers to explore new trends and future directions of the global biopharmaceutical industry. We warmly welcome experts, scholars and industry colleagues to visit and communicate with us.

 

We look forward to meeting you in Boston this May to explore the cutting-edge frontiers of gene and cell therapy innovation!

 

 

Conference Name: 2026 ASGCT Annual Meeting Dates: May 11 - 15, 2026 Venue: Boston Convention and Exhibition Center

 

 

MingCeler Biotech is committed to the development and industrial application of leading next-generation animal model technology — TurboMice™ tetraploid complementation technology. Breaking through the limitations of traditional mouse model preparation, our technology effectively solves the pain points of long modeling cycles and low success rates for complex gene-edited models. We can generate fully homozygous gene-edited mouse models directly from embryonic stem cells in as little as two months, efficiently meeting urgent research demands and greatly saving R&D time and costs for global biomedical researchers and pharmaceutical projects.